4D pharma reports encouraging progress

BIO-medical company 4D Pharma says it has made good progress in its research project exploring the treatment of irritable bowel syndrome.

The Manchester company, which floated in February 2014, raising more than £16m is focused on an area of science called live biotherapeutics.

Its latest market update relates to a trade-marked programme called Blautix, which it says could be used to develop tratements beyond Irritable bowel syndrome (IBS).

It said: "Through its work on the Blautix™ programme... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...